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ABSTRACT 
A new analytical method using high-performance liquid chromatography coupled with photo diode array detection was developed and validated 
for the quantification of Diclofenac (DIC) from in vitro skin permeation samples. Analysis was performed using a Phenomenex C18 column (150 x 
4.6mm, 5µm) with 10mM ammonium acetate: Acetonitrile (62:38% v/v) as the mobile phase in isocratic mode and eluents were monitored at 
276nm. DIC was eluted at 3.1min and showed a good linearity in the concentration range of 0.2-3µg/mL with a correlation coefficient >0.999. 
The validation parameters, such as specificity, linearity, accuracy and limit of detection, limit of quantification, precision, robustness fulfilled the 
regulatory requirements. The developed HPLC method was successfully used for the analysis of DIC in samples obtained from transdermal 
diffusate samples. 
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INTRODUCTION 
Diclofenac sodium (DIC) is a non- steroidal anti-
inflammatory analgesic drug with the potent cyclooxygenase 
inhibition activity 1-5. It is commonly used for pain control 
and treatment of rheumatic diseases. Various analytical 
procedures have been reported for the determination of DIC 
in pharmaceutical preparations including UV-Visible 
spectrophotometry 6-7, chemometry 8, spectrofluorimetry 9, 
high performance liquid chromatography 10-12 etc. Some of 
the methods used UV spectrometry for the estimation of DIC 
in transdermal studies 13-15. Only one method was reported 
for HPLC evaluation of a transdermal patch 16. Literature 
study revealed that there were no validated RP-HPLC-PDA 
methods reported for the estimation of DIC in in vitro skin 
diffusion studies. Hence, the present investigation was aimed 
to develop and validate a rapid and economic RP-HPLC-PDA 
method for the analysis of DIC in transdermal Diffusate 
samples.  
 
EXPERIMENTAL  
Chemicals 
DIC was obtained as a gift sample from Lifeline 
Formulations, Vijayawada. Ammonium acetate, water, 
acetonitrile (ACN) and methanol were purchased from E. 
Merck, Mumbai, India. Sodium chloride was purchased from 
SDFCL, Mumbai, India. All the solvents and reagents used 
were of HPLC grade.  
Equipment 
HPLC system (Shimadzu Prominence) equipped with DGU-
20A3 degasser, LC-20AD binary pumps, SIL-20AHT in-built 
auto sample injecting system, and SPD-M20A PDA detector 
was used. Instrument control, chromatographic data 
processing and analysis were performed using LC solutions 
software. 
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In Vitro Transdermal Diffusion Studies 
For in vitro drug diffusion studies, a vertical type 
transdermal diffusion cell apparatus (Orchid Scientifics, 
Nashik, India) with Franz diffusion cells (having a diffusional 
surface area of 1.77 cm2 and an acceptor volume of ~14 mL) 
were used and normal saline was used as the acceptor fluid 
after sonication. Porcine ear skin was chosen as the specific 
skin model prior to the mounting, skin sample was thawed 
and soaked in saline solution for half an hour for 
equilibration. Skin was mounted in between donor and 
acceptor chambers with the stratum corneum surface facing 
towards donor side and clamped. Magnetic stirring bead was 
placed in the acceptor compartment for uniform stirring of 
the contents. By maintaining the instrument at 37 ± 2 ºC, the 
skin surface is maintained at 32 ºC. 500µL of saturated 
solution of DIC in propylene glycol: saline (70:30 v/v) was 
added to donor chamber. Periodical samples of 500 µL were 
collected through the sampling port and stored at 4C until 
analysis. An equal volume of fresh saline was replenished at 
each sampling point. Sink condition is kept through the 
entire duration of the study was carried out over a 48 hr 
period and the samples were analyzed for DIC content by 
developed HPLC method. 
Chromatographic Conditions 
Isocratic elution with the mobile phase consisting of 10mM 
ammonium acetate: ACN (62:38% v/v) was used. Mobile 
phase was filtered through nylon disc filter of 0.45µm 
(Millipore) and sonicated for 3 min before use. C18 
Phenomenex column (150 × 4.6mm, 5µ) was used as 
stationary phase and maintained at ambient temperature. 
The flow rate was 1.0 mL/min and the injection volume were 
20µL. PDA detection was performed at 276nm and the 
separation was achieved at ambient temperature. 
Preparation of stock and standard solutions 
The stock solution of DIC (1mg/mL) was prepared by 
dissolving 10 mg of DIC in 5mL of methanol and volume was 
adjusted to the mark (10 mL) with the same. An appropriate 
volume of the stock solution was then further diluted with 
10mM Ammonium acetate (as diluent) to get the required 
standard concentrations at a concentration range of 0.2-
3µg/mL 
Validation of the HPLC method 
Following method development and optimization, analytical 
method validation was performed in line with the 
recommendations of the International Conference on 
Harmonization of Technical Requirements for Registration of 
Pharmaceuticals for Human Use (ICH) Q2 (R1) guideline 17 
comprising the following performance parameters: 
Linearity 
A series of five DIC standards were prepared over a 
concentration range of 0.2-3μg/mL (0.2, 0.5, 1, 2, 3μg/mL) 
from the stock and injected in triplicate. Linearity was 
evaluated by a plot of peak areas as a function of analyte 
concentration, and the data was subjected to regression 
analysis where by slope, intercept, and regression (R2) 
correlation coefficients (R) were calculated and the data was 
given in Table-1. 
Precision 
Precision is the measure of closeness of the data values to 
each other for a given number of measurements under the 
same analytical conditions and was assessed by using a 
minimum of six determinations at 100% of the test 
concentration. The standard deviation (SD) and the % 
relative standard deviation (RSD) were reported and the 
data was given in Table-1. 
Specificity  
The specificity of the method was determined by comparing 
the chromatograms obtained from the DIC with that of the 
samples obtained from transdermal permeation studies. The 
overlay of diluent, standard and sample chromatograms was 
shown in Fig. 2 and 3D plots were shown in Fig. 3.   
Accuracy 
To ascertain the accuracy of the proposed method, recovery 
studies were performed by the standard addition method 
where 80, 100, 120% of the known quantities of standard 
concentrations were added to the transdermal permeation 
studies samples and these solutions were analyzed by the 
developed method in triplicate. The % recovery and the % 
RSD values were calculated at each level of addition and the 
data was given in Table-1. 
Limit of Detection (LOD) and Limit of Quantification 
(LOQ) 
LOD and LOQ were calculated based on calibration curve 
data. They were expressed as LOD = (3.3 ×σ)/m; LOQ= 
(10.0×σ)/m (Where,  is the standard deviation of the y-
intercepts of the three regression lines and m is mean of the 
slopes of the three calibration curves). 
Robustness 
To show the robustness of the method developed, the LC 
conditions were deliberately altered and the 
chromatographic parameters viz., tailing factor, number of 
theoretical plates were recorded. To study the effect of flow 
rate, the flow rate was changed by ±5% and the effect of 
wavelength was studied by changing wavelength by ±2nm. 
Whereas, the effect of mobile phase composition was studied 
by changing ± 2% and the data was given in Table-2. 
System suitability 
System suitability was carried out by injecting a standard 
concentration at different injection volumes in the range of 
10-50μL. The system suitability test parameters like 
retention time, tailing factor and theoretical plate number 
were noted and % RSD was calculated. 
Stability of the stock solution 
The stability of the stock solution was determined by 
analyzing the samples stored under refrigeration (8 ± 1o C) 
conditions at different time intervals up to 1 month. 
RESULTS AND DISCUSSION 
Various HPLC, UV and spectrofluorimetric methods were 
published for the estimation of DIC in bulk and dosage forms, 
but no validated HPLC methods were reported for the 
quantification of DIC in in vitro transdermal permeation 
studies. Hence, the present investigation was aimed to 
develop a rapid and economical RP-HPLC-PDA method for 
the determination of DIC in transdermal permeation studies. 
Method Development 
Initially, mobile phase optimization was carried with Agilent 
Eclipse (150x4.6 mm, 5µ) column using 0.02%v/v formic 
acid: methanol at different ratios with a flow rate of 1 
mL/min. With different mobile phase combinations tried, 
DIC was eluted as a broad peak with tailing. In other trial 
Inertsil ODS (250 x 4.6mm, 5µ) column with water and 
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acetonitrile (38:62% v/v) as mobile phase was used at a flow 
rate of 1 mL/min and under these conditions the DIC peak 
merged with solvent front. Further trials were performed on 
Inertsil ODS (250x4.6mm, 5µ) column with 10mM 
ammonium acetate: acetonitrile as mobile phase 
combinations and finally a 62:38% v/v combination of 
10mM ammonium acetate: acetonitrile was selected at flow 
rate of 1.0mL/min with 10mM ammonium acetate as diluent. 
Under these conditions a sharp peak of DIC was eluted at 
3.1min (Fig. 1) and the tailing factor, peak symmetry, 
theoretical plate numbers were all within the limits. For 
quantitative analytical purpose wavelength was set at 276 
nm, which provided better reproducibility with no 
interference. The peak purity index was found to be greater 
than 0.9999 and indicating purity of the DIC sample used in 
the analysis and shown in Fig. 1 along with UV spectrum. 
 
0.0 1.0 2.0 3.0 4.0 min
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
mAU
276nm,4nm (1.00)
3.
11
1
 
2.95 3.00 3.05 3.10 3.15 3.20 3.25 3.30 3.35 3.40 3.45 3.50 min
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
0.0
2.5
5.0
7.5
10.0
12.5
15.0
mAU
Peak
Zero Line
Purity  Curv e
200.0 225.0 250.0 275.0 300.0 325.0 350.0 375.0 nm
0
25
50
75
mAU
 3.20/ 1.00/smth
2
5
0
3
6
0
3
8
0
2
0
4
2
8
1
3
8
7
 
Figure 1: A – Standard chromatogram of DIC (1 µg/mL), B - Peak purity index of DIC and C - UV spectrum of DIC 
 
Method validation 
To establish the suitability of the optimized HPLC method for 
its intended purpose, the developed method has been 
validated in compliance with ICH-Guidelines with respect to 
the following parameters. 
Linearity 
The range of reliable quantification was set at the 
concentrations of 0.2-3μg/mL. Peak areas and 
concentrations were subjected to least square regression 
analysis. The correlation coefficient (R) was found to be 
0.999 indicating a linear response over the concentration 
range selected and the data was given in Table-1. 
Precision 
Precision studies were carried out in terms of repeatability. 
Repeatability of standard application was assessed by using 
six replicates of concentration at 1µg/mL level and the data 
was given in Table-1. The % RSD was found to be below 2 for 
peak areas and this shows the closeness of the data values to 
each other, indicating the precision of the method. 
Specificity 
The specificity of the method was established by injecting 
the solutions of diluent, standard and in vitro transdermal 
permeation sample individually to examine any interference 
and from the overlay of chromatograms as shown in Fig. 2. It 
can be inferred that there were no co-eluting peaks at the 
retention time of DIC, this shows that peak of analyte was 
pure without any interferences and the peak purity indices 
for sample and standard was found to be greater than 0.999 
and this confirms specificity of the method. The absence of 
interference peaks as supported by 3D plots of 
chromatograms, indicates the specificity of the proposed 
method.
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Figure 2: Overlay of the diluent (A), standard (B) and permeation sample (C) chromatograms 
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A                                                            B                                                               C 
Figure 3: 3D Plots of diluent (A), standard (B) and permeation sample (C) 
 
Accuracy 
Accuracy of the proposed method was ascertained by 
performing recovery studies by standard addition method by 
spiking the known quantities of standard at 80, 100, 120% to 
transdermal permeation samples and these solutions were 
analyzed in triplicate in each level of addition. The % RSD 
and the % recovery were within the acceptable limit in all 
cases. From the results obtained, it is evident that the 
proposed method enables very accurate quantitative 
estimation of DIC. 
Table 1: Linearity, Precision and Accuracy data of DIC 
Validation data of DIC 
Linearity(n=3) 
Range 
Regression equation 
Regression coefficient (R2) 
Correlation coefficient (R) 
 
0.2-3µg/mL 
y =29263x-2227 
R=0.999 
R2=0.999 
Accuracy(n=3) 
(% level of addition) 
Mean Recovery 
 (% RSD) 
80 
100 
120 
99.533 (0.30) 
100.533 (0.75) 
98.513 (0.45) 
Precision(n=6) 
 
Average Peak Area (% RSD) 
30914.3 (0.74) 
  
Limit of Detection (LOD) and Limit of Quantification 
(LOQ) 
LOD and LOQ were determined based on statistical 
calculation from the calibration curves, where LOD = (3.3 
×σ)/m; LOQ= (10.0×σ)/m ( is the standard deviation of the 
y-intercepts of the three regression lines and m is mean of 
the slopes of the three calibration curves). The LOD for DIC 
was found to be 0.00852g/mL, the drug peak could be 
detected without any base line disturbances at this 
concentration. The LOQ for DIC was found to be 0.02581 
g/mL 
Robustness  
As part of the robustness, a deliberate change in the flow 
rate, wavelength and mobile phase was made to evaluate the 
impact on the method. Retention times were significantly 
changed with flow rate, mobile phase and no change in the 
retention time was observed in wavelength change. The 
parameters like theoretical plate number, tailing factor were 
not changed and were within the limits. These results 
indicated that the method is robust in terms of flow rate, 
mobile phase and wavelength. 
 
Table 2: Robustness data 
Chromatographic parameter Retention time (min) Theoretical plates (#) Tailing factor  
Flow rate (mL/min) 
0.95 
1.0 
1.05 
3.25 
3.11 
3.05 
2499 
2472 
2463 
1.641 
1.629 
1.614 
Wave length (nm) 
274 
276 
278 
3.11 
3.11 
3.11 
2588 
2472 
2566 
1.632 
1.629 
1.642 
Composition of mobile phase (10mM ammonium acetate: Acetonitrile) 
60:40 
62:38 
64:36 
3.06 
3.11 
3.27 
2469 
2472 
2546 
1.618 
1.629 
1.632 
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System suitability  
System suitability testing is an integral part of the analytical 
procedure. System suitability studies were carried out by 
different injection volumes (10L - 50L) of 1g/mL. The % 
RSD values for system suitability test parameters like 
retention time (1.13%), tailing factor (1.981%) and 
theoretical plate number (1.68%) were less than 2% 
indicating the present conditions were suitable for the 
analysis of DIC in in vitro transdermal permeation samples. 
Stability of the stock solution 
The variation in assay values at different time intervals were 
found to be less than 2% of the initial time interval and these 
results indicate that, the solutions were stable for a period of 
1 month when stored at 8oC.  
In vitro transdermal permeation studies 
The application of this method has been demonstrated by 
the study of in vitro transdermal Diffusate samples of DIC.  
Samples showed no interference peak at DIC elution i.e. 3.1 
min. Permeation profile was shown in Fig. 4. From the 
permeation profile the steady state transdermal flux was 
found to be 13.07nmol/ cm2/ hr, with a lag time of 
16.4293hrs. The amount of DIC retained in the skin after the 
transdermal permeation study was also estimated by the 
developed method. The method was successfully used for the 
quantification of DIC in the skin permeation studies. 
 
Fig.4: In vitro skin permeation profile of DIC 
CONCLUSION 
In this work, a rapid and efficient RP-HPLC-PDA method was 
developed for the analysis of DIC in samples obtained from 
transdermal permeation studies. The method was validated 
as per ICH Guidelines, and found to be applicable for the 
estimation of DIC in in vitro transdermal permeation studies 
using isocratic binary mode of elution. The results of 
linearity, precision, accuracy and specificity were found to be 
within the limits. The method provides selective 
quantification of DIC without interferences from diluent and 
skin diffusion experiments. Therefore, this method can be 
selectively employed to quantify DIC in in vitro transdermal 
permeation studies using saline as the receptor solution. 
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